HealthLinx, in collaboration with ARL Pathology, this week launched OvPlex, an early-stage test for ovarian cancer detection, in Australia.
OvPlex detects the presence of five protein biomarkers linked to ovarian caner in patient blood samples. HealthLinx claims that its biomarker panel can detect cancer with greater accuracy than the biomarker CA125.
In clinical trials, the test yielded 89.2 percent sensitivity and 93.9 percent specificity.
The test will be available through general practitioners in Melbourne before being rolled out to other states in Australia. The test will cost $200 and results will be available in 14 days.
HealthLinx said in a statement that it is continuing research and development on a next-generation ovarian cancer diagnostic with improved accuracy.